Latest & greatest articles for ramipril

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ramipril or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ramipril and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ramipril

21. Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study

Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study Hart W M, Rubio-Terres C, Pajuelo F, Juanatey J R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of ramipril, an angiotensin-converting enzyme (ACE) inhibitor, for the treatment of heart failure after acute myocardial infarction (AMI). The initial dosage was 2.5 mg twice daily. The treatment was initiated between day 3 and day 10 after AMI (day 1 = day of index infarction). Type of intervention Treatment

NHS Economic Evaluation Database.2002

22. Use of ramipril in preventing stroke: double blind randomised trial.

Use of ramipril in preventing stroke: double blind randomised trial. 11909785 2002 03 22 2002 04 16 2014 06 12 1756-1833 324 7339 2002 Mar 23 BMJ (Clinical research ed.) BMJ Use of ramipril in preventing stroke: double blind randomised trial. 699-702 To determine the effect of the angiotensin converting enzyme inhibitor ramipril on the secondary prevention of stroke. Randomised controlled trial with 2x2 factorial design. 267 hospitals in 19 countries. 9297 patients with vascular disease (...) or diabetes plus an additional risk factor, followed for 4.5 years as part of the HOPE study. Stroke (confirmed by computed tomography or magnetic resonance imaging when available), transient ischaemic attack, and cognitive function. Blood pressure was recorded at entry to the study, after 2 years, and at the end of the study. Reduction in blood pressure was modest (3.8 mm Hg systolic and 2.8 mm Hg diastolic). The relative risk of any stroke was reduced by 32% (156 v 226) in the ramipril group compared

BMJ2002 Full Text: Link to full Text with Trip Pro

23. An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus

An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus Beard S M, Gaffney L, Backhouse M E Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of ramipril (Tritace), an angiotensin-converting enzyme inhibitor, for the prevention of cardiovascular disease (CVD) in patients with Type II diabetes mellitus. The dose of ramipril was 10 mg once daily. Type of intervention Primary prevention. Economic study

NHS Economic Evaluation Database.2001

24. Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of ramipril efficacy in nephropathy (REIN) study for Germany from the perspective of statutory health insurance

Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of ramipril efficacy in nephropathy (REIN) study for Germany from the perspective of statutory health insurance Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of ramipril efficacy in nephropathy (REIN) study for Germany from the perspective of statutory health insurance Cost effectiveness of ramipril in patients with non (...) -diabetic nephropathy and hypertension: economic evaluation of ramipril efficacy in nephropathy (REIN) study for Germany from the perspective of statutory health insurance Schadlich P K, Brecht J G, Brunetti M, Pagano E, Rangoonwala B, Huppertz E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

NHS Economic Evaluation Database.2001

25. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies

Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies Ruggenenti P, Pagano E, Tammuzzo L, Benini R, Garattini L, Remuzzi G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of ramipril to delay the progression of chronic renal disease to end-stage renal disease (ESRD) in patients with non-diabetic chronic nephropathies. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population consisted of patients with non-diabetic chronic nephropathies. Setting The study setting was hospital

NHS Economic Evaluation Database.2001

26. Cost effectiveness of ramipril treatment for cardiovascular risk reduction

Cost effectiveness of ramipril treatment for cardiovascular risk reduction Cost effectiveness of ramipril treatment for cardiovascular risk reduction Cost effectiveness of ramipril treatment for cardiovascular risk reduction Malik I S, Bhatia V K, Kooner J S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology The angiotensin-converting enzyme inhibitor ramipril was compared with placebo for the treatment of patients with different risk of cardiovascular death. Type of intervention Primary and secondary prevention. Economic study type Cost-effectiveness analysis. Study population The cost-effectiveness of ramipril was evaluated in three hypothetical cohorts of 66-year-old males from the UK. These were: a low-risk group

NHS Economic Evaluation Database.2001

27. Ramipril and the development of diabetes.

Ramipril and the development of diabetes. 11597291 2001 10 12 2001 11 01 2016 10 17 0098-7484 286 15 2001 Oct 17 JAMA JAMA Ramipril and the development of diabetes. 1882-5 Type 2 diabetes is a growing clinical and public health problem. Preventive efforts related to lifestyle modification are not always successful; therefore, alternative prevention strategies need to be studied. To investigate the effectiveness of ramipril, an angiotensin-converting enzyme inhibitor, in preventing diabetes (...) among high-risk persons. The randomized, controlled Heart Outcomes Prevention Evaluation trial of 5720 patients older than 55 years without known diabetes but with vascular disease who were followed up for a mean of 4.5 years. The study included 267 hospitals in 19 countries and was conducted between 1994 and 1999. Patients were randomly assigned to receive ramipril, up to 10 mg/d (n = 2837), or placebo (n = 2883). Diagnosis of diabetes determined from self-report at follow-up visits every 6 months

JAMA2001

28. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. 11386927 2001 06 01 2001 06 28 2016 10 17 0098-7484 285 21 2001 Jun 06 JAMA JAMA Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. 2719-28 Incidence of end-stage renal disease due to hypertension has increased in recent decades, but the optimal strategy for treatment of hypertension to prevent renal failure is unknown (...) , especially among African Americans. To compare the effects of an angiotensin-converting enzyme (ACE) inhibitor (ramipril), a dihydropyridine calcium channel blocker (amlodipine), and a beta-blocker (metoprolol) on hypertensive renal disease progression. Interim analysis of a randomized, double-blind, 3 x 2 factorial trial conducted in 1094 African Americans aged 18 to 70 years with hypertensive renal disease (glomerular filtration rate [GFR] of 20-65 mL/min per 1.73 m(2)) enrolled between February 1995

JAMA2001

29. Economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events

Economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events Economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events Economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events Backhouse M E, Richter A, Gaffney L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Oral ramipril (10 mg once per day) was compared with placebo ("conventional practice") in patients at high cardiovascular risk. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients at high cardiovascular risk, but without left ventricular dysfunction

NHS Economic Evaluation Database.2000

30. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. 10675071 2000 03 09 2000 03 09 2015 06 16 0140-6736 355 9200 2000 Jan 22 Lancet (London, England) Lancet Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation (...) Study Investigators. 253-9 Diabetes mellitus is a strong risk factor for cardiovascular and renal disease. We investigated whether the angiotensin-converting-enzyme (ACE) inhibitor ramipril can lower these risks in patients with diabetes. 3577 people with diabetes included in the Heart Outcomes Prevention Evaluation study, aged 55 years or older, who had a previous cardiovascular event or at least one other cardiovascular risk factor, no clinical proteinuria, heart failure, or low ejection fraction

Lancet2000

31. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. 10639539 2000 01 21 2000 01 21 2013 11 21 0028-4793 342 3 2000 Jan 20 The New England journal of medicine N. Engl. J. Med. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. 145-53 Angiotensin (...) -converting-enzyme inhibitors improve the outcome among patients with left ventricular dysfunction, whether or not they have heart failure. We assessed the role of an angiotensin-converting-enzyme inhibitor, ramipril, in patients who were at high risk for cardiovascular events but who did not have left ventricular dysfunction or heart failure. A total of 9297 high-risk patients (55 years of age or older) who had evidence of vascular disease or diabetes plus one other cardiovascular risk factor and who

NEJM2000

32. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction: economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) Study for Germany from the perspective of statutory health insurance

Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction: economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) Study for Germany from the perspective of statutory health insurance Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction: economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) Study for Germany from the perspective of statutory health insurance Cost-effectiveness analysis of ramipril in heart (...) failure after myocardial infarction: economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) Study for Germany from the perspective of statutory health insurance Schadlich P K, Huppertz E, Brecht J G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions

NHS Economic Evaluation Database.1998

33. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy.

Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. 9788454 1998 11 10 1998 11 10 2015 06 16 0140-6736 352 9136 1998 Oct 17 Lancet (London, England) Lancet Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (...) (GISEN). Ramipril Efficacy in Nephropathy. 1252-6 The Ramipril Efficacy In Nephropathy (REIN) study found that in patients with chronic nephropathies and proteinuria of 3 g or more per 24 h, ramipril safely reduced the rate of decline of the glomerular filtration rate (GFR) and halved the combined risk of doubling of serum creatinine or end-stage renal failure (ESRF), as compared with placebo plus conventional antihypertensive drugs at the same level of blood pressure control. At the end of the core

Lancet1998

34. Cost effectiveness in the treatment of heart failure with ramipril: a Swedish substudy of the AIRE study

Cost effectiveness in the treatment of heart failure with ramipril: a Swedish substudy of the AIRE study Cost effectiveness in the treatment of heart failure with ramipril: a Swedish substudy of the AIRE study Cost effectiveness in the treatment of heart failure with ramipril: a Swedish substudy of the AIRE study Erhardt L, Ball S, Andersson F, Bergentoft P, Martinez C. Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Adding the angiotensin converting enzyme (ACE) inhibitor ramipril to conventional treatment in patients with heart failure after acute myocardial infarction (AMI). Type of intervention Treatment and secondary prevention. Economic study type Cost-effectiveness analysis. Study population Patients with clinical

NHS Economic Evaluation Database.1997

35. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.

Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. 9167457 1997 06 24 1997 06 24 2015 06 16 0140-6736 349 9064 1997 May 24 Lancet (London, England) Lancet Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. 1493-7 In the Acute (...) Infarction Ramipril Efficacy (AIRE) Study, the effect of angiotensin-converting-enzyme (ACE) inhibition on the survival of patients with clinical heart failure after acute myocardial infarction (AMI), was assessed. At an average follow-up time of 15 months after randomisation, all-cause mortality was reduced from 22.6% (placebo group) to 16.9% (ramipril group) representing an absolute mortality reduction of 5.7% and a relative risk reduction of 27% (95% CI 11-40%; p = 0.002). Our aim in this study

Lancet1997

36. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) 9217756 1997 07 28 1997 07 28 2015 06 16 0140-6736 349 9069 1997 Jun 28 Lancet (London, England) Lancet Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure (...) in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) 1857-63 In diabetic nephropathy, angiotensin-converting-enzyme (ACE) inhibitors have a greater effect than other antihypertensive drugs on proteinuria and the progressive decline in glomerular filtration rate (GFR). Whether this difference applies to progression of nondiabetic proteinuric nephropathies is not clear. The Ramipril Efficacy in Nephropathy study of chronic nondiabetic nephropathies

Lancet1997

37. Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure

Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure Lubsen J, Chadha D R, Yotof Y T, Swedberg K Authors' objectives To assess the effects of ramipril (...) interventions included in the review Ramipril (long-acting, nonsulfhydryl angiotensin-converting enzyme inhibitor with pharmacological properties allowing once-daily administration). Participants included in the review Patients with chronic congestive heart failure, aged 18 to 80 years, with ejection fraction less than 40% or heart size greater than 600 mL/m2 (men) or 550 mL/m2 (women). Outcomes assessed in the review Mortality, hospitalisation, subjective functional status as assessed by NYHA

DARE.1996

38. Cost-effectiveness of ramipril therapy for patients with clinical evidence of heart failure after acute myocardial infarction

Cost-effectiveness of ramipril therapy for patients with clinical evidence of heart failure after acute myocardial infarction Cost-effectiveness of ramipril therapy for patients with clinical evidence of heart failure after acute myocardial infarction Cost-effectiveness of ramipril therapy for patients with clinical evidence of heart failure after acute myocardial infarction Martinez C, Ball S G Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Ramipril therapy in patients showing clinical evidence of heart failure after acute myocardial infarction. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients showing clinical evidence of heart failure after an acute

NHS Economic Evaluation Database.1995

39. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.

Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. 8104270 1993 10 21 1993 10 21 2015 06 16 0140-6736 342 8875 1993 Oct 02 Lancet (London, England) Lancet Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (...) . In this selected high-risk subset of patients we investigated the effect of therapy with the angiotensin converting enzyme (ACE) inhibitor rampiril, postulating that it would lengthen survival. 2006 patients who had shown clinical evidence of heart failure at any time after an acute myocardial infarction (AMI) were recruited from 144 centres in 14 countries. Patients were randomly allocated to double-blind treatment with either placebo (992 patients) or ramipril (1014 patients) on day 3 to day 10 after AMI

Lancet1993

40. Change in cough reflex after treatment with enalapril and ramipril.

Change in cough reflex after treatment with enalapril and ramipril. 2547470 1989 09 19 1989 09 19 2016 11 23 0959-8138 299 6690 1989 Jul 01 BMJ (Clinical research ed.) BMJ Change in cough reflex after treatment with enalapril and ramipril. 13-6 To find out whether enalapril or ramipril causes the sensitivity of the cough reflex to change or symptomatic cough to develop in patients with hypertension. Prospective, placebo controlled, double blind, randomised crossover study. Academic units (...) of clinical pharmacology and medicine. 20 Patients (nine men and 11 women) who needed to take angiotensin converting enzyme inhibitors to control hypertension. All patients received enalapril 10 mg daily, ramipril 10 mg daily, or placebo daily for one week in random order, with a washout period of at least one week between treatments. For assessment of sensitivity of the cough reflex the patients inhaled various concentrations of capsaicin solution in random order. Measurement of the doses of capsaicin

BMJ1989 Full Text: Link to full Text with Trip Pro